

Press Release

Lund, SWEDEN – November 24, 2008

Hansa Medical changes certified adviser

As of December 1, 2008, Hansa Medical AB (publ) will change its certified adviser from Kaupthing Bank Sverige AB to Remium AB. The Hansa Medical share is traded on First North under the ticker symbol HMED.

For more information, please contact:

Emanuel Björne, CEO

Mobile: +46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

Henrik Acklén, Remium AB

Telephone: +46 8 454 32 00

E-mail: henrik.acklen@remium.com

ABOUT HANSA MEDICAL

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company's long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical's lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including antibody-based treatment of rheumatoid arthritis and diagnostics and drugs for sepsis.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund, SWEDEN
TELEPHONE +46 46 16 56 70
FAX +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund, SWEDEN